By analyzing PRMT3 expression in HCC patients who received immunotherapy, we found that PRMT3 was notably higher in tumor samples from patients who received anti-PD-1/PD-L1 therapy at both mRNA and protein levels than in tumor samples from patients who did not (Fig. 2A, B and Supplementary Fig. 4A). This evidence concerns the gene PRMT3 and hepatocellular carcinoma.